Search Results for "DMARDs"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for DMARDs. Results 1 to 5 of 5 total matches.
See also: Neoral
Flowchart: Rheumatoid Arthritis Treatment (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
TNFi failedbDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic ...
View the Flowchart: Rheumatoid Arthritis Treatment
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
and prevent irreversible
joint damage.
CONVENTIONAL DMARDs — Disease-modifying
antirheumatic drugs (DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis (online only) ...
View Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
with a conventional DMARD
is recommended for patients who have had an inadequate
response to methotrexate alone ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
should not be used with other JAK
inhibitors, biologic DMARDs, or other potent
immunosuppressants ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor upadacitinib (Rinvoq – Abbvie) for treatment
of moderately to severely active ulcerative colitis in
adults who have had an inadequate response to or
cannot tolerate one or more tumor necrosis factor
(TNF) inhibitors. Upadacitinib is the second JAK
inhibitor to be approved for this indication; tofacitinib
(Xeljanz) was the first. Upadacitinib is also approved
for treatment of rheumatoid arthritis, psoriatic
arthritis, atopic dermatitis, and ankylosing spondylitis.